Compare First Trust Cloud Computing ETF (SKYY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs GeneDx Holdings Corp — how do they compare? First Trust Cloud Computing ETF trades at $174.89 (market cap $3.47B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: First Trust Cloud Computing ETF is the larger of the two by market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 85 Days and GeneDx Holdings Corp for 19 Days on average.
| SKYY | WGS | |
|---|---|---|
Market Cap | $3.47B | $2.02B |
Volume | 176,159 | 734,640 |
52-Week High | $171.01 | $167.51 |
52-Week Low | $104.16 | $34.51 |
Typical Hold Time | 85 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SKYY (First Trust Cloud Computing ETF) trades at $174.885, up 2.4% with strong bullish technical signals from moving averages. The ETF recently hit a 52-week high, benefiting from AI-driven cloud computing demand. Technical indicators show bullish momentum with support at $169 and resistance at $171. The fund provides diversified exposure to cloud infrastructure and software companies without heavy concentration in mega-cap tech stocks.
The outlook remains positive as cloud computing benefits from secular trends including AI adoption and digital transformation. Key risks include sector concentration and market volatility. Institutional activity shows mixed sentiment with some firms trimming positions while broader analyst coverage highlights the ETF's strategic positioning in the growing cloud computing market.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
